The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | The current approach to severity scoring in TA-TMA
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, discusses the current approach to severity scoring for transplant-associated thrombotic microangiopathy (TA-TMA). She highlights several factors currently being used, including the protein-to-creatinine ratio and biomarkers such as C5b-9. Dr Gavriilaki also mentions the need for future studies in other patient populations to better adapt classification and individualize treatment approaches. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We focus mainly on severe TMA. We have current diagnostic consensus criteria on what is severe. We have seen a lot of updates in this educational session that try to include some factors or exclude some others. So main factors right now include protein-to-creatinine ratio, graft-versus-host disease, infection, but biomarkers such as C5b-9 have been also included. We need actually to adapt our work to each patient population...
We focus mainly on severe TMA. We have current diagnostic consensus criteria on what is severe. We have seen a lot of updates in this educational session that try to include some factors or exclude some others. So main factors right now include protein-to-creatinine ratio, graft-versus-host disease, infection, but biomarkers such as C5b-9 have been also included. We need actually to adapt our work to each patient population. So many studies have been performed in the pediatric setting, not so many in the adult setting. And I think in the future, we will see an adaptation of these severe criteria. For right now, for what we’re doing for our patients, I think we have to keep all that in mind, trying to find the right patient that would benefit from the right treatment. And as it is a very severe and life-threatening disease, we have, in my opinion, to provide all the available tools to our patients, all the available drugs, and try to address this multifactorial syndrome from all these angles.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
